IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by First Bancorp Inc ME

First Bancorp Inc ME cut its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,330 shares of the company’s stock after selling 27 shares during the quarter. First Bancorp Inc ME’s holdings in IDEXX Laboratories were worth $738,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of IDXX. Moneta Group Investment Advisors LLC lifted its holdings in IDEXX Laboratories by 121,647.2% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 7,447,279 shares of the company’s stock valued at $3,038,192,000 after acquiring an additional 7,441,162 shares during the period. State Street Corp raised its stake in shares of IDEXX Laboratories by 2.6% during the 2nd quarter. State Street Corp now owns 3,771,574 shares of the company’s stock worth $1,894,198,000 after buying an additional 97,303 shares during the last quarter. Alliancebernstein L.P. raised its stake in shares of IDEXX Laboratories by 6.4% during the 2nd quarter. Alliancebernstein L.P. now owns 3,592,832 shares of the company’s stock worth $1,804,428,000 after buying an additional 214,529 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of IDEXX Laboratories by 1.4% during the 1st quarter. Geode Capital Management LLC now owns 1,946,339 shares of the company’s stock worth $971,569,000 after buying an additional 26,197 shares during the last quarter. Finally, Blair William & Co. IL raised its stake in shares of IDEXX Laboratories by 0.7% during the 3rd quarter. Blair William & Co. IL now owns 1,199,945 shares of the company’s stock worth $524,700,000 after buying an additional 7,812 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other IDEXX Laboratories news, SVP George Fennell sold 8,198 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the transaction, the senior vice president now owns 6,712 shares in the company, valued at approximately $3,851,815.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, SVP George Fennell sold 8,198 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the completion of the transaction, the senior vice president now directly owns 6,712 shares in the company, valued at approximately $3,851,815.44. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Brian P. Mckeon sold 23,326 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total value of $13,296,053.26. Following the sale, the chief financial officer now directly owns 29,718 shares in the company, valued at $16,939,557.18. The disclosure for this sale can be found here. Insiders sold a total of 43,524 shares of company stock worth $24,871,960 in the last 90 days. 2.11% of the stock is owned by company insiders.

IDEXX Laboratories Stock Down 1.1 %

NASDAQ IDXX opened at $518.10 on Friday. The stock has a market cap of $43.03 billion, a PE ratio of 51.45, a P/E/G ratio of 2.87 and a beta of 1.26. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $583.39. The business has a 50 day moving average price of $548.67 and a two-hundred day moving average price of $504.48. The company has a quick ratio of 1.17, a current ratio of 1.57 and a debt-to-equity ratio of 0.42.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, February 5th. The company reported $2.32 earnings per share for the quarter, topping analysts’ consensus estimates of $2.12 by $0.20. The firm had revenue of $901.60 million during the quarter, compared to analysts’ expectations of $891.88 million. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. IDEXX Laboratories’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.05 EPS. As a group, sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.15 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IDXX has been the subject of several analyst reports. BNP Paribas initiated coverage on shares of IDEXX Laboratories in a research note on Thursday, December 7th. They issued an “outperform” rating and a $602.00 target price for the company. Piper Sandler downgraded shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective for the company. in a research note on Tuesday, January 30th. StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Wednesday, December 20th. Barclays upped their price objective on shares of IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Finally, William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a research note on Friday, January 5th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $591.50.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.